Literature DB >> 32248073

Impact of antibiotic use during curative treatment of locally advanced head and neck cancers with chemotherapy and radiotherapy.

Pablo Nenclares1, Sheerang A Bhide2, Helena Sandoval-Insausti3, Pierre Pialat4, Lucinda Gunn2, Alan Melcher2, Kate Newbold2, Christopher M Nutting2, Kevin J Harrington2.   

Abstract

BACKGROUND: Pre-clinical evidence suggests reduced efficacy of anticancer treatment in patients exposed to broad-spectrum antibiotics. It is hypothesised that this phenomenon may be explained by the effects of antibiotics on the composition of the microbiota. To assess this in a clinical setting, we analysed the impact of antibiotics in patients with locally advanced head and neck cancer (LAHNC) treated with curative intent with chemotherapy and radiotherapy (RT).
MATERIAL AND METHODS: Retrospective data for LAHNC patients treated with curative intent (245 induction chemotherapy followed by chemoradiation [CRT], 17 surgery followed by post-operative CRT, six CRT, three RT alone and one RT with concurrent cetuximab) were analysed. We evaluated the impact of antibiotics prescribed during primary anti-cancer treatment on progression-free survival (PFS), overall survival (OS) and disease-specific survival (DSS) rates by multivariate Kaplan-Meier and Cox proportional hazards regression analysis.
RESULTS: Among 272 patients, those receiving antibiotics between within 1 week before and 2 weeks after treatment (N = 124) progressed significantly earlier and had lower OS and DSS rates. In the multivariate analysis, administration of antibiotics was independently associated with reduced PFS (hazards ratio [HR] 1.98, P = 0.001), OS (HR 1.85, P = 0.001) and DSS (HR 1.95, P = 0.004). This effect was maintained with independence of reason for prescription, type and time of antibiotic prescription. The negative impact was greater for patients who received two or more courses of antibiotics. Antibiotic treatment was correlated with increased risk of locoregional relapse.
CONCLUSIONS: Our data suggest a negative impact of antibiotic therapy on treatment outcomes following CRT with curative intent in patients with LAHNC. This potential harm should be considered when prescribing broad-spectrum and prophylactic antibiotics for such patients.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Anti-bacterial agents; Chemotherapy; Head and neck neoplasms; Microbiota; Radiotherapy

Year:  2020        PMID: 32248073     DOI: 10.1016/j.ejca.2020.02.047

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  9 in total

Review 1.  Targeting the gut and tumor microbiota in cancer.

Authors:  Elizabeth M Park; Manoj Chelvanambi; Neal Bhutiani; Guido Kroemer; Laurence Zitvogel; Jennifer A Wargo
Journal:  Nat Med       Date:  2022-04-19       Impact factor: 87.241

2.  Antibiotic use reduces efficacy of tyrosine kinase inhibitors in patients with advanced melanoma and non-small-cell lung cancer.

Authors:  N Tinsley; C Zhou; S Nahm; S Rack; G C L Tan; P Lorigan; F Blackhall; N Cook
Journal:  ESMO Open       Date:  2022-04-27

3.  Translational model of melphalan-induced gut toxicity reveals drug-host-microbe interactions that drive tissue injury and fever.

Authors:  H R Wardill; C E M de Mooij; A R da Silva Ferreira; I P van de Peppel; R Havinga; H J M Harmsen; W J E Tissing; N M A Blijlevens
Journal:  Cancer Chemother Pharmacol       Date:  2021-04-20       Impact factor: 3.333

Review 4.  The Emerging Roles of Human Gut Microbiota in Gastrointestinal Cancer.

Authors:  Qianqian Guo; Hai Qin; Xueling Liu; Xinxin Zhang; Zelong Chen; Tingting Qin; Linlin Chang; Wenzhou Zhang
Journal:  Front Immunol       Date:  2022-06-15       Impact factor: 8.786

Review 5.  Elucidating the gut microbiota composition and the bioactivity of immunostimulatory commensals for the optimization of immune checkpoint inhibitors.

Authors:  Romain Daillère; Bertrand Routy; Anne-Gaëlle Goubet; Alexandria Cogdill; Gladys Ferrere; Carolina Alves-Costa Silva; Aurélie Fluckiger; Pierre Ly; Yacine Haddad; Eugenie Pizzato; Cassandra Thelemaque; Marine Fidelle; Marine Mazzenga; Maria Paula Roberti; Cléa Melenotte; Peng Liu; Safae Terrisse; Oliver Kepp; Guido Kroemer; Laurence Zitvogel; Lisa Derosa
Journal:  Oncoimmunology       Date:  2020-07-20       Impact factor: 8.110

Review 6.  Trial watch : the gut microbiota as a tool to boost the clinical efficacy of anticancer immunotherapy.

Authors:  Romain Daillère; Lisa Derosa; Mélodie Bonvalet; Nicola Segata; Bertrand Routy; Manuela Gariboldi; Eva Budinská; I Jolanda M De Vries; Alessio Gordon Naccarati; Valérie Zitvogel; Carlos Caldas; Lars Engstrand; Sibylle Loilbl; Jacques Fieschi; Lucie Heinzerling; Guido Kroemer; Laurence Zitvogel
Journal:  Oncoimmunology       Date:  2020-06-03       Impact factor: 8.110

Review 7.  Risk Factors for Infections, Antibiotic Therapy, and Its Impact on Cancer Therapy Outcomes for Patients with Solid Tumors.

Authors:  Ondřej Kubeček; Pavla Paterová; Martina Novosadová
Journal:  Life (Basel)       Date:  2021-12-11

Review 8.  The Interplay among Radiation Therapy, Antibiotics and the Microbiota: Impact on Cancer Treatment Outcomes.

Authors:  Kavery Nivana Theethira Poonacha; Tomás G Villa; Vicente Notario
Journal:  Antibiotics (Basel)       Date:  2022-03-02

Review 9.  Cancer pharmacomicrobiomics: targeting microbiota to optimise cancer therapy outcomes.

Authors:  Nick Lung-Ngai Ting; Harry Cheuk-Hay Lau; Jun Yu
Journal:  Gut       Date:  2022-03-11       Impact factor: 31.793

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.